Related Experiment Video
Updated: Jan 28, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Longer survival in patients with metastatic uterine leiomyosarcoma treated with trabectedin: A case report
Théophraste Henry1, Elizabeth Fabre2, Laurent S Baccar3
1Assistance Publique-Hôpitaux de Paris, Louis Mourier Hospital, Medical Oncology Unit, Department of Medicine, 92700 Colombes, France.
Abstract:
Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline rings. In the present case report, two patients with advanced and metastatic uterine leiomyosarcomas (ULMS) with significant progression-free survival (PFS) and overall survival (OS) administered Trabectedin as second and third line treatment are reported. The first case received third line Trabectedin with a PFS of 24 months and an OS of 35 months. The second case received second line Trabectedin with a PFS of 24 months and an OS of 30 months. In addition, a good safety record was obtained in the long-term administration of Trabectedin (more so in case 1 than case 2), with a good quality of life.
More Related Videos
Related Concept Videos
Uterine Tubes
Data Reporting and Recording
Survival Tree
Building a Survival Tree
Constructing a...
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Comparing the Survival Analysis of Two or More Groups

